US20150320963A1 - Intermittent dosing of nitric oxide gas - Google Patents
Intermittent dosing of nitric oxide gas Download PDFInfo
- Publication number
- US20150320963A1 US20150320963A1 US14/804,114 US201514804114A US2015320963A1 US 20150320963 A1 US20150320963 A1 US 20150320963A1 US 201514804114 A US201514804114 A US 201514804114A US 2015320963 A1 US2015320963 A1 US 2015320963A1
- Authority
- US
- United States
- Prior art keywords
- nitric oxide
- gas
- concentration
- oxide gas
- delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
- A61M16/122—Preparation of respiratory gases or vapours by mixing different gases with dilution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/04—Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0666—Nasal cannulas or tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/08—Bellows; Connecting tubes ; Water traps; Patient circuits
- A61M16/0816—Joints or connectors
- A61M16/0833—T- or Y-type connectors, e.g. Y-piece
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A61M16/202—Controlled valves electrically actuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
- A61M16/202—Controlled valves electrically actuated
- A61M16/203—Proportional
- A61M16/204—Proportional used for inhalation control
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H33/00—Bathing devices for special therapeutic or hygienic purposes
- A61H33/14—Devices for gas baths with ozone, hydrogen, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/1005—Preparation of respiratory gases or vapours with O2 features or with parameter measurement
- A61M2016/102—Measuring a parameter of the content of the delivered gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3327—Measuring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
Definitions
- the field of the present invention relates to methods and devices for delivery of exogenous or gaseous nitric oxide gas to mammals.
- NO is an environmental pollutant produced as a byproduct of combustion. At extremely high concentrations (generally at or above 1000 ppm), NO is toxic. NO also is a naturally occurring gas that is produced by the endothelium tissue of the respiratory system. In the 1980's, it was discovered by researchers that the endothelium tissue of the human body produced NO, and that NO is an endogenous vasodilator, namely, an agent that widens the internal diameter of blood vessel.
- NO has been investigated for the treatment of patients with increased airway resistance as a result of emphysema, chronic bronchitis, asthma, adult respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease, (COPD),
- ARDS adult respiratory distress syndrome
- COPD chronic obstructive pulmonary disease
- the FDA approved the marketing of nitric oxide gas for use with persistent pulmonary hypertension in term and near term newborns. Because the withdrawal of inhaled nitric oxide from the breathing gas of patients with pulmonary hypertension is known to cause a severe and dangerous increase in PVR, referred to as a “rebound effect”, nitric oxide trust be delivered to these patients on a continuous basis.
- NO may also be introduced as a anti-microbial agent against pathogens via inhalation or by topical application. See e.g., WO 00/30659, U.S. Pat. No. 6,432,077, which are hereby incorporate by reference in their entirety.
- the application of gaseous nitric oxide to inhibit or kill pathogens is thought to be beneficial given the rise of numerous antibiotic resistant bacteria. For example, patients with pneumonia or tuberculosis may not respond to antibiotics given the rise of antibiotic resistant strains associated with these conditions.
- nitric oxide for inhalation has conventionally been limited to low concentration of nitric oxide given the potential toxicity.
- the toxicity may stern from binding of nitric oxide to hemoglobin that give rise methemoglobin or from the conversion of nitric oxide gas to nitrogen dioxide (NO 2 ).
- NO 2 nitrogen dioxide
- a method and device delivering intermittent high doses of nitric oxide for a period of time and which cycles between high and low concentration of nitric oxide is desirable, useful, and overcomes the problems of toxicity.
- the high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. This keeps the exposure to the high concentrations of nitric oxide required to overwhelm the nitric oxide defense mechanisms of the pathogens to an average level that is safe for humans to inhale.
- high concentration of nitric oxide may be delivered at a concentration between 80 ppm to 300 ppm, preferably between 150 ppm to 250 ppm, and more preferably between 160 ppm to 200 ppm.
- Low concentration of nitric oxide preferably is delivered at a concentration between zero (0) ppm to 80 ppm, and preferably at a concentration of 20 ppm to 40 ppm.
- the time periods may vary and in a wide range that preferably will deliver a dose of x time of 600 to 1000 ppmhrs per day.
- the method would deliver 160 ppm for 30 minutes every four hours with 20 ppm delivered for the 3.5 hours between the higher concentration delivery.
- High concentration may also be delivered for a period of time between 10 minutes to 45 minutes, and the low concentration is preferably delivered for a period of time longer than the period of time in which the high concentration is delivered.
- it may also be delivered for the same length of time as the high concentration of nitric oxide with less number of cycles to achieve substantially the same amount of ppmhrs of nitric oxide per day.
- the high and low concentrations are alternately delivered, and the cycling of the delivery can be ⁇ bra day, two days, three days, or any other time prescribed by a physician.
- Devices for the delivery of nitric oxide are commercially available and may include continuous flow devices, flow matching devices, or pulse dose devices.
- the FDA has already approved three different nitric oxide delivery systems in the United States; AeroNOx® Delivery System and the ViaNOx DS System (Pulmonox, Canada) and the INOvent® Delivery System (Datex-Ohmeda, Wisconsin).
- Other devices have also been described in literature and various publications and patents (e.g., U.S. Pat. No. 6,581,599, which is incorporated here by reference in its entirety).
- the device for use to deliver intermittent high doses of nitric oxide may include a source of nitric oxide gas (e.g., nitric oxide gas in compressed gas cylinders), controller (e.g. an electronic controller or microprocessor), nitric oxide analyzer, and timer in which the concentration of nitric oxide delivered is automatically changed on a timed basis to a concentration set by the operator and for a set period of time defined by the operator.
- the device would include logic (e.g. software or firmware) that allows for setting of two different nitric oxide concentrations and with separate time settings for the delivery of each concentration.
- the device may also include gas mixers (such as gas blenders or combinations of flow control valves and T or Y shaped tube connections), tubings, a source of diluent gas (e.g. room air, oxygen, or inert gas), and electronically regulated needle valves or other valve mechanism for controlling the release of nitric oxide gas, or the diluent gas, or both.
- gas mixers such as gas blenders or combinations of flow control valves and T or Y shaped tube connections
- tubings e.g. room air, oxygen, or inert gas
- a source of diluent gas e.g. room air, oxygen, or inert gas
- electronically regulated needle valves or other valve mechanism for controlling the release of nitric oxide gas, or the diluent gas, or both.
- the device may also include two sources of nitric oxide gas, in which one source provides the high concentration of nitric oxide and the other source provides the low concentration of nitric oxide.
- a switch valve (preferably electronically controlled) is then provided to switch the flow of nitric oxide gas from the high concentration to the low concentration, or vice versa, based on a predefined time.
- a third source of diluent gas may also be provided to dilute the nitric oxide gas.
- FIGS. 1-3 illustrate schematic representations of various embodiments of a nitric oxide delivery device according to one aspect of the present invention.
- FIG. 4 illustrates the logic for setting the alternating delivery profile for high and low concentrations of nitric oxide gas.
- FIG. 5 illustrates the logic for delivering alternating high and low concentrations of nitric oxide gas.
- FIG. 6 shows the effect on survival of S. aureus (ATCC#25923) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours.
- NO gas gNO
- FIG. 7 shows the effect on survival of P. aeruginosa (ATCC#27853) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours.
- NO gas gNO
- FIG. 8 shows the effect on survival of P. aeruginosa (clinical strain from Cystic Fibrosis) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours.
- NO gas gNO
- FIG. 9 shows the effect on survival of E. coli when alternately exposed to NO gas (gNO) at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours.
- NO gas gNO
- FIG. 10 shows the effect on survival of a MshA mycothiol deficient mutant Mycobacterium smegmatis and its wild type counterpart when exposed to 200 ppm NO gas (gN0).
- FIG. 11 shows the level of mycothiol in wild type Mycobacterium smegmatis when exposed to 400 ppm NO gas (gNO) compared to exposure to air.
- gNO ppm NO gas
- nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system.
- the thiol defense system may include for example, the mycothiol for mycobacterium or glutathione for other bacteria. Once this defense mechanism is depleted, the pathogen is defenseless against the killing effects of nitric oxide.
- a lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens to prevent them from rebuilding their defense system to an adequate level.
- a preferred therapeutic or delivery profile for combating pathogens may comprise the delivery of a first concentration of nitric oxide gas for a number of time periods interspersed with intervals in between wherein a second concentration of nitric oxide is administered during the intervals.
- the first concentration is preferably at a high concentration sufficient to kill or inhibit microbial growth.
- the first concentration may range from about 80 ppm to 400 ppm, more preferably between 150 to 250 ppm and most preferably between 160 ppm to 200 ppm.
- the second concentration is preferably at low concentration of nitric oxide gas such as ranging from 20 to 80 ppm. Alternatively, it should also be understood that the second concentration can also be zero ppm or close to trace amount of nitric oxide gas.
- FIGS. 1-3 illustrate various embodiments of a nitric oxide delivery device for use with the present invention.
- FIG. 1 shows, in its most general sense, a NO delivery device 2 that includes a source of nitric oxide gas 8 adapted. for delivery of the NO gas to a mammal through a delivery interface 6 .
- FIG. 1 illustrates one preferred embodiment of the invention.
- the NO gas source 8 is a pressurized cylinder containing NO gas. While the use of a pressurized cylinder is the preferred method of storing the NO-containing gas source 8 , other storage and delivery means, such as a dedicated feed line (wall supply) can also be used. Typically, the NO gas source 8 is a mixture of N 2 and NO. While N 2 is typically used to dilute the concentration of NO within the pressurized cylinder, any inert gas can also be used. When the NO gas source 8 is stored in a pressurized cylinder, it is preferable that the concentration of NO in the pressurized cylinder fall within the range of about 800 ppm to about 10,000 ppm.
- nitric oxide manufacturers typically produce nitric oxide mixtures for medical use at around the 1000 ppm range.
- Pressurized cylinders containing low concentrations of NO e.g., less than 100 ppm NO
- concentrations of NO e.g., less than 100 ppm NO
- FIG. 1 also shows a source of diluent gas 14 as part of the NO delivery device 2 that is used to dilute the concentration of NO.
- the source of diluent gas 14 can contain N 2 , O 2 , Air, an inert gas, or a mixture of these gases. It is preferable to use a gas such as N 2 or an inert gas to dilute the NO concentration at lower concentration since these gases will not oxidize the NO into NO 2 as would O 2 or air. Nevertheless, for inhalation applications for delivery of high concentration of NO where higher concentration of open may already be present, the NO flow may be supplemented or diluted with oxygen to prevent the displacement of oxygen by nitrogen that may lead to asphyxiation. It is preferred, especially when delivering higher concentration of NO gas that delivery line downstream of the injection site or gas blender be minimized to reduce the sac of formation of NO 2 .
- the source of diluent gas 14 is shown as being stored within a pressurized cylinder. While the use of a pressurized cylinder is shown in FIG. 1 as the means for storing the source of diluent gas 14 , other storage and delivery means, such as a dedicated feed line (wall supply) can also be used.
- the source of diluent gas can also be a ventilator, air pump, blower, or other mechanical device that moves breathable air.
- the NO gas from the NO gas source 8 and the diluent gas from the diluent gas source 14 preferably pass through pressure regulators 16 to reduce the pressure of gas that is admitted to the NO delivery device 2 .
- the respective gas streams pass via tubing 18 to a gas blender 20 .
- the gas blender 20 mixes the NO gas and the diluent gas to produce a NO-containing gas that has a reduced concentration of NO compared to NO gas contained in the source 8 .
- a controller 36 controls the gas blender through electrical connection line 42 such that gas blender can be set to mix the gases to the desired NO concentration (e.g., 160 ppm-200 ppm for the high concentration period, and 20-40 ppm for the low concentration period) and output via tubing 24 .
- the desired NO concentration e.g. 160 ppm-200 ppm for the high concentration period, and 20-40 ppm for the low concentration period
- An optional flow control valve 22 can be located downstream of the gas blender 20 to control the flow of the NO gas to the delivery interface 6 .
- the flow control valve 22 can include, for example, a proportional control valve that opens (or closes) in a progressively increasing (or decreasing if closing) manner.
- the flow control valve 22 can include a mass flow controller. The flow control valve 22 controls the flow rate of the NO-containing gas that is input to the delivery device 6 .
- the delivery interface 6 can be any type of interface adaptable for delivery of the gas to a mammal.
- the delivery interface 6 may include a facial mask, nasal insert, or endotracheal tube that interface with the mammal's respiratory system.
- the types of delivery interface 6 should not be limiting and depends on the specific applications and locations for the delivery of the gas.
- a bathing unit as described in U.S. Pat. No. 6,432,077, issued to one of the inventors may be used.
- U.S. Pat. No. 6,432,077 is hereby incorporated by reference as if fully set forth herein.
- a delivery interface 6 may an interface to a dialysis circuit or extracorporeal circuitry wherein the NO gas is delivered directly to the blood or body fluids so as to expose the blood or body fluids to NO gas.
- Such delivery interface are described, for example, in U.S. patent application Ser. No. 10/658,665, filed on Sep. 9, 2003, which is hereby incorporated by reference in its entirety.
- the delivery device 2 preferably includes a controller 36 that is capable of controlling the flow control valve 22 and the gas blender 20 .
- the controller 36 is preferably a microprocessor-based controller 36 that is connected to an input device (not shown).
- the input device may be used by an operator to adjust various parameters of the delivery device such as NO concentration and therapy/exposure time periods.
- An optional display can also be connected with the controller 36 to display measured parameters and settings such as the set-point NO concentration, the concentration of NO flowing to the delivery interface 6 , the concentration of NO2, the flow rate of gas into the delivery interface 6 , the total time of therapy/delivery, and/or the number of cycles for alternating between high and low concentrations of NO gas.
- the controller preferably includes a timer for counting down the time periods of the NO gas delivery at the different concentrations. Moreover, the controller preferably includes, logic such as firmware or software programs for executing the alternate delivery of high and low concentration of NO gas at pre-set or user programmable time periods. The processes for execution by such logic are illustrated in FIGS. 4 and 5 .
- the controller 36 also preferably receives signals through signal line 48 from NO analyzer 40 regarding gas concentrations if such analyzer 40 are present within the delivery device 2 .
- Signal lines 42 and 44 are connected to the gas blender 20 and flow control valve 22 respectively for the delivery and receipt of control signals.
- the controller 36 may be eliminated entirely and the gas blender 20 may be set manually at the desired high or low concentration of nitric oxide gas.
- the time period may also be tracked manually and at the appropriate set time period, the gas blender is adjusted to either increase to the high concentration NO gas or decrease to the low concentration NO gas.
- the flow rate of the gas into the delivery interface 6 may be pre-set or adjusted manually.
- FIG. 2 shows an alternative embodiment of a nitric oxide delivery device 52 in which the desired concentration of NO gas is achieved by mixing with a T or Y shaped connection 70 based on the flow rates of the NO gas flowing from the NO gas source 8 and the diluent gas flowing from the diluent gas source 74 .
- the respective flow rates are controlled via the flow control valves 72 and 75 .
- Mixing of the gases starts at the T or Y shaped connection point 70 and continues through the delivery line 78 .
- An NO analyzer 80 samples the gas mixture at a juncture close to the delivery interface to determine the NO concentration of the gas mixture flowing to the delivery interface 76 .
- the measured NO concentration is then fed back through signal line 88 to the controller 86 , which in turn processes the information by comparing the measured NO concentration with the set desired NO gas concentration.
- the controller 86 then adjusts the flow control valves 72 and 75 , if appropriate, by sending control signals through lines 82 and 84 such that the flow rate(s) may be adjusted in order to achieve the desired concentration of NO gas flowing to the delivery interface 76
- the controller 86 may similarly include all the features discussed above in connection with controller 36 in FIG. 1 .
- the delivery interface 76 may be adapted similarly to the delivery interface 6 , as described in connection with FIG. 1 .
- FIG. 3 illustrates yet another embodiment of a nitric oxide delivery device in accordance to one aspect of the present invention.
- the delivery device 102 instead of having gas mixers (e.g., gas blender or T or Y-shaped connection), the delivery device 102 utilizes a switch valve 104 to switch between a high concentration NO gas source 106 and a low concentration NO gas source 108 .
- the switch valve 104 is controlled by the controller 116 that at the appropriate time switches between the high and low concentration of NO gas according to the present invention.
- the low concentration NO gas source 108 can also be replaced with non-NO gas source such as air, if the desired period of low NO concentration is zero ppm of NO gas.
- FIG. 4 illustrates a process flow for setting up the desired concentrations and time periods for NO gas delivery starting from Step 400 “START.”
- the logic enters the setup subroutine for setting the desired NO concentrations and time periods.
- the logic verifies if there are concentration values set for the NO delivery profile. If values are already set, then the process proceeds to Step 415 to verify the values set for the time periods of delivery.
- the logic calls a subprocess comprising of steps 412 and 414 is called to set the 1 st and 2 nd NO concentration for the therapeutic profile to be delivered.
- the 1 st NO concentration may be set for about 160 ppm to 300 ppm of NO gas to be delivered and the 2 nd concentration may be set for 0 ppm to 80 ppm of NO gas to be delivered.
- the values of the NO concentrations set are then used by the controller to set the gas blender or the flow control valves in the process illustrated in FIG. 5 .
- the logic then proceeds to set the time periods for the delivery of the NO gas in Step 415 . If the time periods have not yet been set, then a subprocess comprising steps 417 and 149 is called in which a first time period corresponding to the 1 st NO concentration and a 2 nd time period corresponding to the NO concentration are set.
- the logic then proceeds to set the number of cycles of alternating 1 st and 2 nd concentration of NO gas to be delivered.
- a total therapy time can be set in which the delivery of NO gas will cease at the end of the total therapy time. If the total therapy time or number of cycles have not been set, then a subprocess comprising of step 422 is called and these values are set. Afterwards, the setup process is ended and the device is ready to deliver NO gas for therapy.
- FIG. 5 illustrates a process flow for execution by the logic in controller 36 , 56 , and 116 , for the alternating delivery of high and low concentration of NO gas.
- the START THERAPY in step 500 can be started once the NO gas delivery values in FIG. 4 has been entered.
- the controller 36 may then send a control signal through line 42 to the gas blender to set the appropriate gas blender settings to achieve the 1 st concentration of NO gas, the value of which was set in the setup process of FIG. 4 .
- This process may also include feedback control from the NO analyzer 40 ( FIG. 1 ) to the controller 36 such that the control of the gas blender may be fine tuned in that the actual NO gas concentration being delivered to the delivery interface 6 matches the set NO gas concentration.
- the controller at Step 505 may send control signals to the flow control valves 72 and 75 ( FIG. 2 ) to set the appropriate flow, rates for the mixing of the gases to achieve the 1 st concentration set in the setup process of FIG. 4 .
- This process may similarly include feedback control from the NO analyzer 80 ( FIG. 2 ) to the controller 56 .
- the controller at Step 505 may set the switch valve 104 ( FIG. 3 ) to select for delivery the NO gas from a source corresponding to the 1 st concentration of NO gas set in the setup process of FIG. 4 .
- Step 510 the timer comprised in the controller 36 , 56 , or 116 compares the value of the 1 st time period set in FIG. 4 with the actual countdown in time. If the time period has not elapsed, then the gas blender, flow control valves, or switch valve settings remain the same in Step 512 . If the 1 st time period has elapsed, then step 515 sets the gas blender, flow rates, or switch valve settings to that corresponding to the 2 nd concentration of NO gas, the value of which was set in the process of FIG. 4 . Delivery of NO gas then proceeds on the 2 nd concentration until the 2nd time period elapsed.
- step 525 inquiring into whether the set number of cycles of total therapy time has elapsed. If the set number of cycles or total therapy time has been reached, the therapy ends in Step 530 . Otherwise, the process repeats steps 505 , 510 , 515 , and 525 .
- the implementation of the intermittent delivery of high doses of NO gas can be by many means.
- delivery by inhalation or to the respiratory airway can be made to spontaneously breathing mammals or those managed with mechanical ventilation.
- spontaneously breathing mammals delivery can be achieved via many of previously described gas delivery systems such as masks or nasal cannulas.
- the device for these mammals may include flowmeter or flow sensor to detect the onset of breathing (e.g., inhalation vs. exhalation) such that the nitric oxide gas would be delivered only when the mammal inhales.
- Mechanically ventilated mammals would have the nitric oxide delivered into the inspiratory limb of the ventilator circuit and may similarly be triggered only when the ventilator cycled a breath into the mammal.
- the pattern of nitric oxide delivery may vary depending on the targeted location of the infection within the mammal's lungs and the desire to have the least concentration of nitric oxide residual in the delivery circuit. For example, if the infection were in the air sacs of the lungs, the nitric oxide could be turned off towards the end of the breath when the gas was going to be delivered only to the airways. As an alternative, if the infection were only in the airways, then the starting gas might have a lower concentration of nitric oxide.
- the injection site for NO gas delivery be close to the patient's airway when using higher concentrations of NO gas so as to reduce the time for conversion to NO 2 , This minimizes the dwell time of the NO gas in the delivery line before inhalation.
- the delivery system may utilize a bolus injection of a high concentration at a time point within the breath and allow the dilution of the NO to occur within the lungs.
- Inoculums of varying bacteria was prepared to a suspension of 2.5 ⁇ 10 8 cfu/ml, and diluted 1:1000 in sterile normal saline. Three milliliters of the inoculums were used per well in a sterile culture place. Exposure of the inoculums were performed in an exposure chamber, which has been described for example, in Gliafarri, A. et al., “A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures,” Nitric Oxide.
- FIGS. 6-9 show the survival of various bacteria used in the experiment with NO gas compared to exposure to air as control. As seen in these figures, cycling exposure to high and low concentrations of nitric oxide is an effective method of killing the bacteria. While it was observed that the effectiveness of cycling exposure to high and low concentrations over a longer period of time, was similar to that of continuous exposure to high concentration, cycling exposure provides a better safety profile in minimizing the risk of methemoglobin formation.
- FIG. 10 shows that the mycothiol-deficient MshA mutant was more sensitive to NO gas than its wild type counterpart and was killed in less time than its wild type counterpart.
- FIG. 11 shows that upon exposure to 400 ppm of NO gas, the level of mycothiol in the mycobacterium was reduced compared to exposure to air.
- the analogous molecule to mycothiol in mycobacteria is glutathione.
- the glutathione pool may normally act to protect the bacteria from endogenous NO and. H 2 O 2 , which are released by macrophages against pathogens. Delivery of exogenous NO gas may thus act to overwhelm the glutathione pool, eliminating bacterial protection from H 2 O 2 , and binding iron based enzymes causing O 2 consumption cessation and electron transport center disruption and freeing metal ions into the bacterial cytosol.
- the free oxygen, metal ions, NO, and hydrogen peroxide further produce reactive nitrogen and oxygen species as well as metal ions that damage the bacteria's DNA by deamination.
- cycling or alternating delivery of concentration of NO gas sufficient to overwhelm the glutathione defense mechanism for a period of time and a lower concentration of NO gas may be effective in combating microbes such as bacteria, mycobacteria, and fungi while at the same time exhibit a better safety profile.
- Microbes may also include viruses. While viruses do not by themselves have thiol based detoxification pathways, they may still be inherently more susceptible to nitrosative stress. NO may inhibit viral ribonucleotide reductase, a necessary constituent enzyme of viral. DNA synthesis and therefore inhibit viral replication. Nitric oxide may also inhibit the replication of viruses early during the replication cycle, involving the synthesis of vIRNA and mRNA encoding viral proteins. With viruses also depending on host cells for detoxification of the body's defense pathways, the direct cytotoxic mechanisms of NO entering the host cells and the intracellular changes it produces, could also account for the viricidal effects through viral DNA deamination. Thus, it is believed that the cycling or alternating delivery of NO gas at high and low concentrations may also be effective against viruses.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Devices For Medical Bathing And Washing (AREA)
Abstract
A method and corresponding device are described for combating microbes and infections by delivering intermittent high doses of nitric oxide to a mammal for a period of time and which cycles between high and low concentration of nitric oxide gas. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. The method is advantageous because at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens and also reduces the risk of toxicity of nitric oxide gas.
Description
- This application is a continuation of U.S. application Ser. No. 11/596,027, filed on Nov. 10, 2006, which is the National Stage entry of International Application No. PCT/US2005/016427, filed May 11, 2005, which claims benefit of U.S. Provisional Application No. 60/570,429, filed May 11, 2004. The disclosure of the prior application is hereby incorporated herein in its entirety by reference.
- The field of the present invention relates to methods and devices for delivery of exogenous or gaseous nitric oxide gas to mammals.
- NO is an environmental pollutant produced as a byproduct of combustion. At extremely high concentrations (generally at or above 1000 ppm), NO is toxic. NO also is a naturally occurring gas that is produced by the endothelium tissue of the respiratory system. In the 1980's, it was discovered by researchers that the endothelium tissue of the human body produced NO, and that NO is an endogenous vasodilator, namely, an agent that widens the internal diameter of blood vessel.
- With this discovery, numerous researchers have investigated the use of low concentrations of exogenously inhaled NO to treat various pulmonary diseases in human patients. See e.g., Higenbottam et al., Am. Rev. Resp. Dis. Suppl. 137:107, 1988. It was determined, for example, that primary pulmonary hypertension (PPH) can be treated by inhalation of low concentrations of NO. With respect to pulmonary hypertension, inhaled NO has been found to decrease pulmonary artery pressure (PAP) as well as pulmonary vascular resistance (PVR). The use of inhaled NO for PPH patients was followed by the use of inhaled NO for other respiratory diseases. For example, NO has been investigated for the treatment of patients with increased airway resistance as a result of emphysema, chronic bronchitis, asthma, adult respiratory distress syndrome (ARDS), and chronic obstructive pulmonary disease, (COPD), In 1999, the FDA approved the marketing of nitric oxide gas for use with persistent pulmonary hypertension in term and near term newborns. Because the withdrawal of inhaled nitric oxide from the breathing gas of patients with pulmonary hypertension is known to cause a severe and dangerous increase in PVR, referred to as a “rebound effect”, nitric oxide trust be delivered to these patients on a continuous basis.
- In addition to its effects on pulmonary vasculature, NO may also be introduced as a anti-microbial agent against pathogens via inhalation or by topical application. See e.g., WO 00/30659, U.S. Pat. No. 6,432,077, which are hereby incorporate by reference in their entirety. The application of gaseous nitric oxide to inhibit or kill pathogens is thought to be beneficial given the rise of numerous antibiotic resistant bacteria. For example, patients with pneumonia or tuberculosis may not respond to antibiotics given the rise of antibiotic resistant strains associated with these conditions.
- Clinical use of nitric oxide for inhalation has conventionally been limited to low concentration of nitric oxide given the potential toxicity. The toxicity may stern from binding of nitric oxide to hemoglobin that give rise methemoglobin or from the conversion of nitric oxide gas to nitrogen dioxide (NO2). However, to overwhelm pathogenic defense mechanisms to nitric oxide, it is desirable to deliver nitric oxide at a higher concentration (e.g., between 150 ppm to 250 ppm, and even to 400 ′ppm) than has traditionally been used clinically for inhalation. Thus, a need exists for a delivery method that is effective against combating pathogens and minimizing the risk of toxicity.
- It is envisioned that a method and device delivering intermittent high doses of nitric oxide for a period of time and which cycles between high and low concentration of nitric oxide is desirable, useful, and overcomes the problems of toxicity. The high concentration of nitric oxide is preferably delivered intermittently for brief periods of time that are interspersed with periods of time with either no nitric oxide delivery or lower concentrations of nitric oxide. This keeps the exposure to the high concentrations of nitric oxide required to overwhelm the nitric oxide defense mechanisms of the pathogens to an average level that is safe for humans to inhale.
- In a preferred embodiment, high concentration of nitric oxide may be delivered at a concentration between 80 ppm to 300 ppm, preferably between 150 ppm to 250 ppm, and more preferably between 160 ppm to 200 ppm. Low concentration of nitric oxide preferably is delivered at a concentration between zero (0) ppm to 80 ppm, and preferably at a concentration of 20 ppm to 40 ppm.
- The time periods may vary and in a wide range that preferably will deliver a dose of x time of 600 to 1000 ppmhrs per day. For example, the method would deliver 160 ppm for 30 minutes every four hours with 20 ppm delivered for the 3.5 hours between the higher concentration delivery. High concentration may also be delivered for a period of time between 10 minutes to 45 minutes, and the low concentration is preferably delivered for a period of time longer than the period of time in which the high concentration is delivered. However, it may also be delivered for the same length of time as the high concentration of nitric oxide with less number of cycles to achieve substantially the same amount of ppmhrs of nitric oxide per day. Thus, the high and low concentrations are alternately delivered, and the cycling of the delivery can be {bra day, two days, three days, or any other time prescribed by a physician.
- Devices for the delivery of nitric oxide are commercially available and may include continuous flow devices, flow matching devices, or pulse dose devices. For example, the FDA has already approved three different nitric oxide delivery systems in the United States; AeroNOx® Delivery System and the ViaNOx DS System (Pulmonox, Canada) and the INOvent® Delivery System (Datex-Ohmeda, Wisconsin). Other devices have also been described in literature and various publications and patents (e.g., U.S. Pat. No. 6,581,599, which is incorporated here by reference in its entirety).
- In another aspect of the invention, the device for use to deliver intermittent high doses of nitric oxide may include a source of nitric oxide gas (e.g., nitric oxide gas in compressed gas cylinders), controller (e.g. an electronic controller or microprocessor), nitric oxide analyzer, and timer in which the concentration of nitric oxide delivered is automatically changed on a timed basis to a concentration set by the operator and for a set period of time defined by the operator. The device would include logic (e.g. software or firmware) that allows for setting of two different nitric oxide concentrations and with separate time settings for the delivery of each concentration. The device may also include gas mixers (such as gas blenders or combinations of flow control valves and T or Y shaped tube connections), tubings, a source of diluent gas (e.g. room air, oxygen, or inert gas), and electronically regulated needle valves or other valve mechanism for controlling the release of nitric oxide gas, or the diluent gas, or both.
- Alternatively, the device may also include two sources of nitric oxide gas, in which one source provides the high concentration of nitric oxide and the other source provides the low concentration of nitric oxide. A switch valve (preferably electronically controlled) is then provided to switch the flow of nitric oxide gas from the high concentration to the low concentration, or vice versa, based on a predefined time. A third source of diluent gas may also be provided to dilute the nitric oxide gas.
-
FIGS. 1-3 illustrate schematic representations of various embodiments of a nitric oxide delivery device according to one aspect of the present invention. -
FIG. 4 illustrates the logic for setting the alternating delivery profile for high and low concentrations of nitric oxide gas. -
FIG. 5 illustrates the logic for delivering alternating high and low concentrations of nitric oxide gas. -
FIG. 6 shows the effect on survival of S. aureus (ATCC#25923) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours. -
FIG. 7 shows the effect on survival of P. aeruginosa (ATCC#27853) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours. -
FIG. 8 shows the effect on survival of P. aeruginosa (clinical strain from Cystic Fibrosis) when alternately exposed to NO gas (gNO) exposure at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours. -
FIG. 9 shows the effect on survival of E. coli when alternately exposed to NO gas (gNO) at 160 ppm nitric oxide gas for 30 minutes and 20 ppm for 3.5 hours for a total exposure time of 24 hours. -
FIG. 10 shows the effect on survival of a MshA mycothiol deficient mutant Mycobacterium smegmatis and its wild type counterpart when exposed to 200 ppm NO gas (gN0). -
FIG. 11 shows the level of mycothiol in wild type Mycobacterium smegmatis when exposed to 400 ppm NO gas (gNO) compared to exposure to air. - It is currently believed that at higher concentration, nitric oxide gas overwhelms the defense mechanism of pathogens that use the mammalian body to replenish their thiol defense system. The thiol defense system may include for example, the mycothiol for mycobacterium or glutathione for other bacteria. Once this defense mechanism is depleted, the pathogen is defenseless against the killing effects of nitric oxide. A lower dose or concentration of nitric oxide gas delivered in between the bursts of high concentration nitric oxide maintains nitrosative stress pressure on the pathogens to prevent them from rebuilding their defense system to an adequate level. Thus, a preferred therapeutic or delivery profile for combating pathogens may comprise the delivery of a first concentration of nitric oxide gas for a number of time periods interspersed with intervals in between wherein a second concentration of nitric oxide is administered during the intervals. The first concentration is preferably at a high concentration sufficient to kill or inhibit microbial growth. For example, the first concentration may range from about 80 ppm to 400 ppm, more preferably between 150 to 250 ppm and most preferably between 160 ppm to 200 ppm.
- The second concentration is preferably at low concentration of nitric oxide gas such as ranging from 20 to 80 ppm. Alternatively, it should also be understood that the second concentration can also be zero ppm or close to trace amount of nitric oxide gas.
- Turning now to the figures,
FIGS. 1-3 illustrate various embodiments of a nitric oxide delivery device for use with the present invention.FIG. 1 shows, in its most general sense, aNO delivery device 2 that includes a source ofnitric oxide gas 8 adapted. for delivery of the NO gas to a mammal through adelivery interface 6.FIG. 1 illustrates one preferred embodiment of the invention. - In
FIG. 1 , theNO gas source 8 is a pressurized cylinder containing NO gas. While the use of a pressurized cylinder is the preferred method of storing the NO-containinggas source 8, other storage and delivery means, such as a dedicated feed line (wall supply) can also be used. Typically, theNO gas source 8 is a mixture of N2 and NO. While N2 is typically used to dilute the concentration of NO within the pressurized cylinder, any inert gas can also be used. When theNO gas source 8 is stored in a pressurized cylinder, it is preferable that the concentration of NO in the pressurized cylinder fall within the range of about 800 ppm to about 10,000 ppm. Commercial nitric oxide manufacturers typically produce nitric oxide mixtures for medical use at around the 1000 ppm range. Pressurized cylinders containing low concentrations of NO (e.g., less than 100 ppm NO) can also be used in accordance with the device and method disclosed herein. Of course, the lower the concentration of NO used, the more often the pressurized cylinders will need replacement. -
FIG. 1 also shows a source ofdiluent gas 14 as part of theNO delivery device 2 that is used to dilute the concentration of NO. The source ofdiluent gas 14 can contain N2, O2, Air, an inert gas, or a mixture of these gases. It is preferable to use a gas such as N2 or an inert gas to dilute the NO concentration at lower concentration since these gases will not oxidize the NO into NO2 as would O2 or air. Nevertheless, for inhalation applications for delivery of high concentration of NO where higher concentration of open may already be present, the NO flow may be supplemented or diluted with oxygen to prevent the displacement of oxygen by nitrogen that may lead to asphyxiation. It is preferred, especially when delivering higher concentration of NO gas that delivery line downstream of the injection site or gas blender be minimized to reduce the sac of formation of NO2. - The source of
diluent gas 14 is shown as being stored within a pressurized cylinder. While the use of a pressurized cylinder is shown inFIG. 1 as the means for storing the source ofdiluent gas 14, other storage and delivery means, such as a dedicated feed line (wall supply) can also be used. The source of diluent gas can also be a ventilator, air pump, blower, or other mechanical device that moves breathable air. - The NO gas from the
NO gas source 8 and the diluent gas from thediluent gas source 14 preferably pass throughpressure regulators 16 to reduce the pressure of gas that is admitted to theNO delivery device 2. The respective gas streams pass viatubing 18 to agas blender 20. Thegas blender 20 mixes the NO gas and the diluent gas to produce a NO-containing gas that has a reduced concentration of NO compared to NO gas contained in thesource 8. Preferably, acontroller 36 controls the gas blender throughelectrical connection line 42 such that gas blender can be set to mix the gases to the desired NO concentration (e.g., 160 ppm-200 ppm for the high concentration period, and 20-40 ppm for the low concentration period) and output viatubing 24. - An optional
flow control valve 22 can be located downstream of thegas blender 20 to control the flow of the NO gas to thedelivery interface 6. Theflow control valve 22 can include, for example, a proportional control valve that opens (or closes) in a progressively increasing (or decreasing if closing) manner. As another example, theflow control valve 22 can include a mass flow controller. Theflow control valve 22 controls the flow rate of the NO-containing gas that is input to thedelivery device 6. - The
delivery interface 6 can be any type of interface adaptable for delivery of the gas to a mammal. For example, if the NO gas is to be delivered to the mammal's airways or lungs, thedelivery interface 6 may include a facial mask, nasal insert, or endotracheal tube that interface with the mammal's respiratory system. It should be understood that the types ofdelivery interface 6 should not be limiting and depends on the specific applications and locations for the delivery of the gas. In another example, if the NO gas is to be delivered topically to a surface of the body such as a skin or eye, a surface of an organ such heart, stomach, etc., a bathing unit as described in U.S. Pat. No. 6,432,077, issued to one of the inventors may be used. U.S. Pat. No. 6,432,077 is hereby incorporated by reference as if fully set forth herein. Still further example of adelivery interface 6 may an interface to a dialysis circuit or extracorporeal circuitry wherein the NO gas is delivered directly to the blood or body fluids so as to expose the blood or body fluids to NO gas. Such delivery interface are described, for example, in U.S. patent application Ser. No. 10/658,665, filed on Sep. 9, 2003, which is hereby incorporated by reference in its entirety. - Still referring to
FIG. 1 , thedelivery device 2 preferably includes acontroller 36 that is capable of controlling theflow control valve 22 and thegas blender 20. Thecontroller 36 is preferably a microprocessor-basedcontroller 36 that is connected to an input device (not shown). The input device may be used by an operator to adjust various parameters of the delivery device such as NO concentration and therapy/exposure time periods. An optional display can also be connected with thecontroller 36 to display measured parameters and settings such as the set-point NO concentration, the concentration of NO flowing to thedelivery interface 6, the concentration of NO2, the flow rate of gas into thedelivery interface 6, the total time of therapy/delivery, and/or the number of cycles for alternating between high and low concentrations of NO gas. - The controller preferably includes a timer for counting down the time periods of the NO gas delivery at the different concentrations. Moreover, the controller preferably includes, logic such as firmware or software programs for executing the alternate delivery of high and low concentration of NO gas at pre-set or user programmable time periods. The processes for execution by such logic are illustrated in
FIGS. 4 and 5 . - The
controller 36 also preferably receives signals throughsignal line 48 from NOanalyzer 40 regarding gas concentrations ifsuch analyzer 40 are present within thedelivery device 2.Signal lines gas blender 20 andflow control valve 22 respectively for the delivery and receipt of control signals. - In another embodiment of the nitric oxide delivery device, the
controller 36 may be eliminated entirely and thegas blender 20 may be set manually at the desired high or low concentration of nitric oxide gas. The time period may also be tracked manually and at the appropriate set time period, the gas blender is adjusted to either increase to the high concentration NO gas or decrease to the low concentration NO gas. The flow rate of the gas into thedelivery interface 6 may be pre-set or adjusted manually. -
FIG. 2 shows an alternative embodiment of a nitricoxide delivery device 52 in which the desired concentration of NO gas is achieved by mixing with a T or Y shapedconnection 70 based on the flow rates of the NO gas flowing from theNO gas source 8 and the diluent gas flowing from thediluent gas source 74. The respective flow rates are controlled via theflow control valves connection point 70 and continues through thedelivery line 78. An NO analyzer 80 samples the gas mixture at a juncture close to the delivery interface to determine the NO concentration of the gas mixture flowing to thedelivery interface 76. The measured NO concentration is then fed back throughsignal line 88 to thecontroller 86, which in turn processes the information by comparing the measured NO concentration with the set desired NO gas concentration. Thecontroller 86 then adjusts theflow control valves lines delivery interface 76 It should be understood that thecontroller 86 may similarly include all the features discussed above in connection withcontroller 36 inFIG. 1 . Likewise, thedelivery interface 76 may be adapted similarly to thedelivery interface 6, as described in connection withFIG. 1 . -
FIG. 3 illustrates yet another embodiment of a nitric oxide delivery device in accordance to one aspect of the present invention. In thisdelivery device 102, instead of having gas mixers (e.g., gas blender or T or Y-shaped connection), thedelivery device 102 utilizes aswitch valve 104 to switch between a high concentrationNO gas source 106 and a low concentrationNO gas source 108. Theswitch valve 104 is controlled by thecontroller 116 that at the appropriate time switches between the high and low concentration of NO gas according to the present invention. It should be understood that the low concentrationNO gas source 108 can also be replaced with non-NO gas source such as air, if the desired period of low NO concentration is zero ppm of NO gas. - Referring now to
FIGS. 4 and 5 , process flows are exemplified that may be executed by logic (firmware or software) programmed into thecontrollers FIG. 4 illustrates a process flow for setting up the desired concentrations and time periods for NO gas delivery starting fromStep 400 “START.” AtStep 405, the logic enters the setup subroutine for setting the desired NO concentrations and time periods. AtStep 410, the logic verifies if there are concentration values set for the NO delivery profile. If values are already set, then the process proceeds to Step 415 to verify the values set for the time periods of delivery. If no values have yet been set for the NO concentrations, then the logic calls a subprocess comprising ofsteps FIG. 5 . - After the values of NO concentrations have been set, the logic then proceeds to set the time periods for the delivery of the NO gas in
Step 415. If the time periods have not yet been set, then asubprocess comprising steps 417 and 149 is called in which a first time period corresponding to the 1st NO concentration and a 2nd time period corresponding to the NO concentration are set. - After the values of NO concentrations and the time periods have been set, the logic then proceeds to set the number of cycles of alternating 1st and 2nd concentration of NO gas to be delivered. Alternatively, a total therapy time can be set in which the delivery of NO gas will cease at the end of the total therapy time. If the total therapy time or number of cycles have not been set, then a subprocess comprising of
step 422 is called and these values are set. Afterwards, the setup process is ended and the device is ready to deliver NO gas for therapy. -
FIG. 5 illustrates a process flow for execution by the logic incontroller step 500 can be started once the NO gas delivery values inFIG. 4 has been entered. AtStep 505, the controller 36 (FIG. 1 ) may then send a control signal throughline 42 to the gas blender to set the appropriate gas blender settings to achieve the 1st concentration of NO gas, the value of which was set in the setup process ofFIG. 4 . This process may also include feedback control from the NO analyzer 40 (FIG. 1 ) to thecontroller 36 such that the control of the gas blender may be fine tuned in that the actual NO gas concentration being delivered to thedelivery interface 6 matches the set NO gas concentration. - Alternatively, the controller at
Step 505 may send control signals to theflow control valves 72 and 75 (FIG. 2 ) to set the appropriate flow, rates for the mixing of the gases to achieve the 1st concentration set in the setup process ofFIG. 4 . This process may similarly include feedback control from the NO analyzer 80 (FIG. 2 ) to the controller 56. In yet another embodiment, the controller atStep 505 may set the switch valve 104 (FIG. 3 ) to select for delivery the NO gas from a source corresponding to the 1st concentration of NO gas set in the setup process ofFIG. 4 . - Delivery of NO gas proceeds in accordance with the settings in
Step 505. Atstep 510, the timer comprised in thecontroller FIG. 4 with the actual countdown in time. If the time period has not elapsed, then the gas blender, flow control valves, or switch valve settings remain the same inStep 512. If the 1st time period has elapsed, then step 515 sets the gas blender, flow rates, or switch valve settings to that corresponding to the 2nd concentration of NO gas, the value of which was set in the process ofFIG. 4 . Delivery of NO gas then proceeds on the 2nd concentration until the 2nd time period elapsed. - At the completion of the second time period, the logic proceeds to step 525 inquiring into whether the set number of cycles of total therapy time has elapsed. If the set number of cycles or total therapy time has been reached, the therapy ends in
Step 530. Otherwise, the process repeatssteps - The implementation of the intermittent delivery of high doses of NO gas can be by many means. For example, delivery by inhalation or to the respiratory airway can be made to spontaneously breathing mammals or those managed with mechanical ventilation. With respect to spontaneously breathing mammals, delivery can be achieved via many of previously described gas delivery systems such as masks or nasal cannulas. The device for these mammals may include flowmeter or flow sensor to detect the onset of breathing (e.g., inhalation vs. exhalation) such that the nitric oxide gas would be delivered only when the mammal inhales. Mechanically ventilated mammals would have the nitric oxide delivered into the inspiratory limb of the ventilator circuit and may similarly be triggered only when the ventilator cycled a breath into the mammal.
- In both of these implementations, the pattern of nitric oxide delivery may vary depending on the targeted location of the infection within the mammal's lungs and the desire to have the least concentration of nitric oxide residual in the delivery circuit. For example, if the infection were in the air sacs of the lungs, the nitric oxide could be turned off towards the end of the breath when the gas was going to be delivered only to the airways. As an alternative, if the infection were only in the airways, then the starting gas might have a lower concentration of nitric oxide.
- Furthermore, it is preferred that the injection site for NO gas delivery be close to the patient's airway when using higher concentrations of NO gas so as to reduce the time for conversion to NO2, This minimizes the dwell time of the NO gas in the delivery line before inhalation. Alternatively, the delivery system may utilize a bolus injection of a high concentration at a time point within the breath and allow the dilution of the NO to occur within the lungs.
- While embodiments of the present invention have been shown and described, various modifications may be made without departing from the scope of the invention. The invention, therefore, should not be limited, except to the following claims, and their equivalents.
- The effectiveness of the intermittent nigh dose delivery of citric oxide gas in combating microorganisms was tested and verified. Briefly, the experimental methods were as follows. Inoculums of varying bacteria was prepared to a suspension of 2.5×108 cfu/ml, and diluted 1:1000 in sterile normal saline. Three milliliters of the inoculums were used per well in a sterile culture place. Exposure of the inoculums were performed in an exposure chamber, which has been described for example, in Gliafarri, A. et al., “A direct nitric oxide gas delivery system for bacterial and mammalian cell cultures,” Nitric Oxide. 12(3):129-40 (May 2005), which is hereby incorporated by reference as if fully set forth herein. The inoculums were exposed to 160 ppm of NO gas at a flow rate of 2.5 liters per minute for 30 minutes followed by exposure to 20 ppm of NO gas for 3.5 hours. The exposure to high and low concentrations of NO gas was repeatedly cycled every 4 hours for 24 hours. At various times (e.g., 0, 4, 8, and 12 hours), samples were taken and plated to determine the survivability of the bacteria as determined by counting cfu/ml.
-
FIGS. 6-9 show the survival of various bacteria used in the experiment with NO gas compared to exposure to air as control. As seen in these figures, cycling exposure to high and low concentrations of nitric oxide is an effective method of killing the bacteria. While it was observed that the effectiveness of cycling exposure to high and low concentrations over a longer period of time, was similar to that of continuous exposure to high concentration, cycling exposure provides a better safety profile in minimizing the risk of methemoglobin formation. - Additional studies were performed to test the hypothesis that the effect of NO gas in killing microorganisms is related to thiol function. Based on studies with various microorganisms, it was observed that Mycobacteria are less sensitive to NO gas damage. This may be due to Mycobacteria having an exceptional thiol, mycothiol, that maintains the redox balance in the cell and protects the cell from nitrosative and oxidative stress. In order to test this hypothesis, sensitivities to NO gas was compared between mycothiol-deficient Mycobacterium smegmatis Mutant MshA to its wild type counterpart, mc2155 by exposing both strains to 200 ppm of NO gas. MshA is an enzyme needed in mycothiol biosynthesis.
-
FIG. 10 shows that the mycothiol-deficient MshA mutant was more sensitive to NO gas than its wild type counterpart and was killed in less time than its wild type counterpart. - Further experiments were conducted to assay and measure the mycothiol level using HPLC in wild type M. smegmatis after exposure to 400 ppm NO gas and were compared to mycothiol level after exposure to air.
FIG. 11 shows that upon exposure to 400 ppm of NO gas, the level of mycothiol in the mycobacterium was reduced compared to exposure to air. - Thus, these results show the NO gas may likely act to deplete mycothiol, which is the mechanism by which the mycobacterium protects itself against oxidative stress.
- In other bacteria, it is believed that the analogous molecule to mycothiol in mycobacteria is glutathione. The glutathione pool may normally act to protect the bacteria from endogenous NO and. H2O2, which are released by macrophages against pathogens. Delivery of exogenous NO gas may thus act to overwhelm the glutathione pool, eliminating bacterial protection from H2O2, and binding iron based enzymes causing O2 consumption cessation and electron transport center disruption and freeing metal ions into the bacterial cytosol. The free oxygen, metal ions, NO, and hydrogen peroxide further produce reactive nitrogen and oxygen species as well as metal ions that damage the bacteria's DNA by deamination. Thus, it is believed that cycling or alternating delivery of concentration of NO gas sufficient to overwhelm the glutathione defense mechanism for a period of time and a lower concentration of NO gas may be effective in combating microbes such as bacteria, mycobacteria, and fungi while at the same time exhibit a better safety profile.
- Microbes may also include viruses. While viruses do not by themselves have thiol based detoxification pathways, they may still be inherently more susceptible to nitrosative stress. NO may inhibit viral ribonucleotide reductase, a necessary constituent enzyme of viral. DNA synthesis and therefore inhibit viral replication. Nitric oxide may also inhibit the replication of viruses early during the replication cycle, involving the synthesis of vIRNA and mRNA encoding viral proteins. With viruses also depending on host cells for detoxification of the body's defense pathways, the direct cytotoxic mechanisms of NO entering the host cells and the intracellular changes it produces, could also account for the viricidal effects through viral DNA deamination. Thus, it is believed that the cycling or alternating delivery of NO gas at high and low concentrations may also be effective against viruses.
Claims (24)
1. A method of delivering nitric oxide to a mammal, the method comprising the steps of:
providing a source of nitric oxide gas;
diluting the nitric oxide gas;
alternately administering, for a number of cycles, the nitric oxide gas to the mammal at a first concentration ranging from about 80 ppm to about 400 ppm of nitric oxide gas for a first period of time and at a second concentration of nitric oxide gas lower than the first concentration for a second period of time.
2. The method of claim 1 wherein the second period of time is longer than the first period of time.
3. The method of claim 1 wherein the first concentration of nitric oxide gas ranges from about 160 ppm to about 300 ppm.
4. The method of claim 1 wherein the second concentration of nitric, oxide ranges from about 20 ppm to about 40 ppm.
5. The method of claim 1 wherein the first period of time is about 30 minutes and the second period of time is about 3.5 hours.
6. The method of claim 1 wherein the step of administering is through inhalation of the nitric oxide gas.
7. The method of claim 1 wherein the step of administering is topical application of the nitric oxide gas.
8. A method of delivering nitric oxide to mammal, the method comprising the step of administering to a mammal a first concentration of nitric oxide gas for a number of time periods that are interspersed with intervals in between wherein a second concentration of nitric oxide is administered during the intervals.
9. The method of claim 8 wherein the second concentration of nitric oxide gas is lower than the first concentration of nitric oxide gas.
10. The method of claim 9 wherein the second concentration of nitric oxide gas is less than about 80 ppm.
11. The method of claim 8 wherein the first concentration of nitric oxide gas is at a concentration sufficient to kill or inhibit the growth of microbes.
12. The method of claim 11 wherein the microbes are selected from a group consisting of bacteria, mycobacteria, viruses and fungi.
13. The method of claim 8 wherein the step of administration is through inhalation of the nitric oxide gas.
14. The method of claim 8 wherein the step of administering is topical application of the nitric oxide-gas.
15. A device for delivery nitric oxide gas comprising:
a source of nitric oxide gas;
a source of diluent gas;
a delivery interface adaptable for delivery of the nitric oxide gas from the source to a mammal;
a gas mixer for mixing the nitric oxide gas with the diluent gas;
a controller that communicates with the gas mixer wherein the controller comprises logic for setting a nitric oxide delivery profile comprising at least two different concentrations of nitric oxide gas and for automatically switching between the at least two different concentrations of nitric oxide gas on a timed basis.
16. The device of claim 15 wherein the delivery profile further comprises at least a first and a second time period corresponding respectively to each of the at least two different concentration of nitric oxide gas.
17. The device of claim 16 wherein the first time period is shorter than the second time period.
18. The device of claim 15 wherein the gas mixer comprises a T or Y shaped tubing connection and a flow control valve.
19. The device of claim 15 wherein the gas mixer comprises a gas blender.
20. The device of claim 15 wherein the delivery interface comprises a bathing unit for topical delivery of nitric oxide gas to a surface of the body.
21. The device of claim 15 wherein the delivery interface comprises an interface selected from a group consisting of facial mask, nasal insert, and endotracheal tube.
22. The device of claim 15 further comprising a nitric oxide gas analyzer for measuring the concentration of nitric oxide gas flowing to the delivery interface, wherein the nitric oxide gas analyzer sends signals to the controller.
23. A device for delivery nitric oxide gas comprising:
a source of nitric oxide gas at a first concentration;
a source of breathable gas;
a delivery interface adaptable for delivery of the nitric oxide gas from the source to a mammal;
a switch valve downstream of the source of nitric oxide gas and upstream of the delivery interface, said switch valve for directing the flow of nitric oxide gas from the source to the delivery interface;
a controller controlling the switch valve and which commands the switch valve to switch between the source of nitric oxide gas and the source of breathable gas on a timed basis.
24. The delivery device of claim, 23 wherein the source of breathable gas comprises nitric oxide gas at a concentration lower than the first concentration of nitric oxide gas.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/804,114 US20150320963A1 (en) | 2004-05-11 | 2015-07-20 | Intermittent dosing of nitric oxide gas |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57042904P | 2004-05-11 | 2004-05-11 | |
PCT/US2005/016427 WO2005110441A2 (en) | 2004-05-11 | 2005-05-11 | Intermittent dosing of nitric oxide gas |
US59602706A | 2006-11-10 | 2006-11-10 | |
US13/007,273 US20110226241A1 (en) | 2004-05-11 | 2011-01-14 | Intermittent dosing of nitric oxide gas |
US13/369,205 US9095534B2 (en) | 2004-05-11 | 2012-02-08 | Intermittent dosing of nitric oxide gas |
US14/804,114 US20150320963A1 (en) | 2004-05-11 | 2015-07-20 | Intermittent dosing of nitric oxide gas |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/369,205 Continuation US9095534B2 (en) | 2004-05-11 | 2012-02-08 | Intermittent dosing of nitric oxide gas |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150320963A1 true US20150320963A1 (en) | 2015-11-12 |
Family
ID=35394664
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/596,027 Abandoned US20080029093A1 (en) | 2004-05-11 | 2005-05-11 | Intermittent Dosing Of Nitric Oxide Gas |
US11/598,221 Active US7955294B2 (en) | 2004-05-11 | 2006-11-10 | Intermittent dosing of nitric oxide gas |
US13/007,273 Abandoned US20110226241A1 (en) | 2004-05-11 | 2011-01-14 | Intermittent dosing of nitric oxide gas |
US13/369,205 Active US9095534B2 (en) | 2004-05-11 | 2012-02-08 | Intermittent dosing of nitric oxide gas |
US14/804,114 Abandoned US20150320963A1 (en) | 2004-05-11 | 2015-07-20 | Intermittent dosing of nitric oxide gas |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/596,027 Abandoned US20080029093A1 (en) | 2004-05-11 | 2005-05-11 | Intermittent Dosing Of Nitric Oxide Gas |
US11/598,221 Active US7955294B2 (en) | 2004-05-11 | 2006-11-10 | Intermittent dosing of nitric oxide gas |
US13/007,273 Abandoned US20110226241A1 (en) | 2004-05-11 | 2011-01-14 | Intermittent dosing of nitric oxide gas |
US13/369,205 Active US9095534B2 (en) | 2004-05-11 | 2012-02-08 | Intermittent dosing of nitric oxide gas |
Country Status (8)
Country | Link |
---|---|
US (5) | US20080029093A1 (en) |
EP (1) | EP1755715A4 (en) |
JP (1) | JP2007537267A (en) |
CN (1) | CN1950120B (en) |
AU (1) | AU2005244078A1 (en) |
CA (1) | CA2563493A1 (en) |
MX (1) | MXPA06013111A (en) |
WO (1) | WO2005110441A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021224894A1 (en) * | 2020-05-08 | 2021-11-11 | Kersten Erich | Ventilator and method of ventilation |
WO2024086364A1 (en) * | 2022-10-21 | 2024-04-25 | Vero Biotech Inc. | Systems, methods, and apparatus for producing nitric oxide |
Families Citing this family (90)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070086954A1 (en) * | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US20080167603A1 (en) * | 2000-12-26 | 2008-07-10 | Alex Stenzler | Method and device to prevent ventilator acquired pneumonia using nitric oxide |
CA2536827C (en) * | 2003-07-09 | 2014-09-16 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US8017074B2 (en) | 2004-01-07 | 2011-09-13 | Noxilizer, Inc. | Sterilization system and device |
WO2005067986A1 (en) * | 2004-01-07 | 2005-07-28 | Noxilizer, Inc. | Sterilization system and device |
US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
US20080029093A1 (en) | 2004-05-11 | 2008-02-07 | Alex Stenzler | Intermittent Dosing Of Nitric Oxide Gas |
US7362274B1 (en) * | 2004-07-09 | 2008-04-22 | Huan-Cheng Lien | Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna |
US9358150B2 (en) * | 2005-05-13 | 2016-06-07 | Benechill, Inc. | Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance |
US8557300B2 (en) * | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
US8893717B2 (en) | 2005-09-21 | 2014-11-25 | Ino Therapeutics Llc | Systems and methods of administering a pharmaceutical gas to a patient |
US7523752B2 (en) | 2005-09-21 | 2009-04-28 | Ino Therapeutics, Llc | System and method of administering a pharmaceutical gas to a patient |
US20070181126A1 (en) * | 2006-02-08 | 2007-08-09 | Tolmie Craig R | Method and apparatus for ventilating a patient with a breathing gas mixture formed from nitric oxide, air, and oxygen |
US8079998B2 (en) | 2006-10-20 | 2011-12-20 | Pulmonox Technologies Corporation | Methods and devices for the delivery of therapeutic gases including nitric oxide |
CA2710349A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide -donating compounds and uses thereof |
WO2010014818A1 (en) * | 2008-07-30 | 2010-02-04 | Nitric Biotherapeutics, Inc. | Methods of treating an infection with nitric oxide |
US20100040703A1 (en) * | 2008-08-13 | 2010-02-18 | Chris Miller | Use of nitric oxide |
US10960168B2 (en) * | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
US8701657B2 (en) * | 2008-08-21 | 2014-04-22 | Geno Llc | Systems for generating nitric oxide |
US8425837B2 (en) | 2009-02-23 | 2013-04-23 | Noxilizer, Inc. | Device and method for gas sterilization |
JP5692561B2 (en) * | 2009-03-23 | 2015-04-01 | エア・ウォーター株式会社 | Medicinal gas administration device |
US20120093948A1 (en) * | 2009-11-20 | 2012-04-19 | Fine David H | Nitric Oxide Treatments |
EP2531249B1 (en) * | 2010-02-01 | 2021-03-24 | VERO Biotech LLC | Nitric oxide delivery system |
DE102010016699A1 (en) * | 2010-04-29 | 2011-11-03 | Maquet Gmbh & Co. Kg | Method and device for applying at least one medical gas to a patient ventilated by means of a ventilator |
DE102010054361B4 (en) * | 2010-12-13 | 2013-02-21 | Nli Gmbh | therapy device |
WO2012094671A2 (en) * | 2011-01-07 | 2012-07-12 | Somerset Group Enterprises, Inc. | Modular extracorporeal systems and methods for treating blood-borne diseases |
EP2678062A1 (en) * | 2011-02-21 | 2014-01-01 | Koninklijke Philips N.V. | Method and arrangement for generating a gas stream comprising nitric oxide |
FR2976259B1 (en) * | 2011-06-09 | 2013-07-05 | Air Liquide | PROCESS FOR CONDITIONING A NO / N2 GAS MIXTURE |
WO2013039713A2 (en) | 2011-09-14 | 2013-03-21 | 3M Innovative Properties Company | Positive pressure medical dressings with valve and kits containing same |
US10426913B2 (en) | 2011-11-07 | 2019-10-01 | Mallinckrodt Hospital Products IP Limited | Apparatus and method for monitoring nitric oxide delivery |
MX362813B (en) * | 2011-11-07 | 2019-02-08 | Mallinckrodt Hospital Products Ip Ltd | Apparatus and method for monitoring nitric oxide delivery. |
MX353210B (en) | 2011-12-21 | 2018-01-08 | Capnia Inc | Collection and analysis of a volume of exhaled gas with compensation for the frequency of a breathing parameter. |
CA2897426A1 (en) * | 2012-01-09 | 2013-07-18 | Somerset Group Enterprises, Inc. | Modular extracorporeal systems and methods for treating blood-borne diseases |
CA2865876A1 (en) * | 2012-03-07 | 2013-09-12 | Advanced Inhalation Therapies (Ait) Ltd. | Inhalation of nitric oxide for treating respiratory diseases |
JP6104513B2 (en) * | 2012-03-09 | 2017-03-29 | エア・ウォーター株式会社 | Ventilator |
AU2013231976B9 (en) * | 2012-03-15 | 2017-12-14 | Mallinckrodt Hospital Products IP Limited | Methods of administering high concentrations of nitric oxide |
US9265922B2 (en) | 2012-04-16 | 2016-02-23 | Astuce, Inc. | System and method for improving outcome of cerebral ischemia |
FR2991026B1 (en) * | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | HIGH PRESSURE PACKAGING OF A NO / NITROGEN GAS MIXTURE |
FR2991025B1 (en) * | 2012-05-24 | 2014-07-04 | Air Liquide Sante Int | CONDITIONING OF A NO / NITROGEN GAS MIXTURE WITH HIGH NO CONCENTRATION |
US20140000596A1 (en) * | 2012-06-29 | 2014-01-02 | Ino Therapeutics Llc | Methods And Apparatus To Zero A Patient Trigger Sensor |
US9364388B2 (en) | 2012-09-27 | 2016-06-14 | Barry university | Methods of treatment with nitric oxide at pressures greater than one atmosphere |
US20140127081A1 (en) * | 2012-11-05 | 2014-05-08 | Geno Llc | Dual platform system for the delivery of nitric oxide |
LT2928531T (en) * | 2012-12-04 | 2017-07-10 | Ino Therapeutics Llc | Cannula for minimizing dilution of dosing during nitric oxide delivery |
BR112015019326A2 (en) | 2013-02-12 | 2017-07-18 | Capnia Inc | respiratory gas sampling and storage recording device |
EP2964302A2 (en) | 2013-03-07 | 2016-01-13 | Advanced Inhalation Therapies (AIT) Ltd. | Inhalation of nitric oxide for treating respiratory diseases |
ES2661099T3 (en) * | 2013-03-13 | 2018-03-27 | Ino Therapeutics Llc | Apparatus for controlling nitric oxide supply |
EP2968827B1 (en) | 2013-03-15 | 2019-02-20 | The General Hospital Corporation | Synthesis of nitric oxide gas for inhalation |
JP6689188B2 (en) | 2013-03-15 | 2020-04-28 | ザ ジェネラル ホスピタル コーポレイション | Inspiratory synthesis of nitric oxide |
CN103982771A (en) * | 2013-05-12 | 2014-08-13 | 摩尔动力(北京)技术股份有限公司 | Hydraulic energy storage tank |
US10335567B2 (en) * | 2013-08-27 | 2019-07-02 | 12th Man Technologies, Inc. | Nitric oxide upper airway delivery system and method |
KR20160050049A (en) | 2013-08-30 | 2016-05-10 | 카프니아, 인코포레이티드 | Neonatal carbon dioxide measurement system |
US20150072023A1 (en) * | 2013-09-11 | 2015-03-12 | Advanced Inhalation Therapies (Ait) Ltd. | Inhalation of nitric oxide for treating respiratory diseases |
US10226592B2 (en) * | 2014-04-01 | 2019-03-12 | Mallinckrodt Hospital Product Ip Limited | Systems and method for delivery of therapeutic gas to patients in need thereof using enhanced breathing circuit gas (BCG) flow measurement |
US9833643B2 (en) * | 2014-04-03 | 2017-12-05 | Mark Squibb | Apparatus for providing controlled flow of inhalation-air |
WO2015157524A1 (en) * | 2014-04-09 | 2015-10-15 | 12th Man Technologies, Inc. | Systems and methods for high concentration nitric oxide delivery |
US10525226B2 (en) * | 2014-05-14 | 2020-01-07 | Mallinckrodt Hospital Products IP Limited | Systems and methods for indicating lifetime of an NO2-to-NO reactor cartridge used to deliver NO for inhalation therapy to a patient |
AU2015336025A1 (en) * | 2014-10-20 | 2017-05-04 | Anish BHATNAGAR | Breath analysis systems and methods for screening infectious diseases |
CN116177503A (en) | 2014-10-20 | 2023-05-30 | 通用医疗公司 | System and method for synthesizing nitric oxide |
US20160121071A1 (en) * | 2014-10-30 | 2016-05-05 | Nu-Med Plus | Controlled delivery of medical gases using diffusion membranes |
EP3020438A1 (en) * | 2014-11-13 | 2016-05-18 | Linde AG | Device for ventilating a patient and method for operating a device for ventilating a patient |
US11633551B2 (en) | 2014-11-13 | 2023-04-25 | Hansen Pharmaceutical, Llc | Gaseous nitric oxide delivery system and methods of use |
WO2016077635A1 (en) | 2014-11-13 | 2016-05-19 | Barry university | Nitric oxide delivery system and methods of use |
JP6719467B2 (en) * | 2014-12-19 | 2020-07-08 | マケット・クリティカル・ケア・アーベー | Additive gas delivery device with backup |
US10039781B2 (en) * | 2015-03-24 | 2018-08-07 | Ait Therapeutics, Inc. | Pulse inhalation of nitric oxide for treating respiratory diseases |
KR102363923B1 (en) * | 2015-09-09 | 2022-02-21 | 어드밴스드 인헐레이션 테라피즈 (에이아이티) 리미티드 | Nitric oxide inhalation therapy for infants with bronchiolitis |
MX2018004020A (en) | 2015-10-01 | 2018-09-11 | Mallinckrodt Hospital Products Ip Ltd | Device and method for diffusing high concentration no with inhalation therapy gas. |
JP6666701B2 (en) * | 2015-12-01 | 2020-03-18 | 日本光電工業株式会社 | Hydrogen gas supply device |
WO2017165888A1 (en) | 2016-03-25 | 2017-09-28 | The General Hospital Corporation | Delivery systems and methods for electric plasma synthesis of nitric oxide |
AU2018223826B2 (en) | 2017-02-27 | 2019-11-07 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
MX2020010523A (en) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Systems and methods for generating nitric oxide. |
EP3585727B1 (en) | 2017-02-27 | 2022-03-16 | Third Pole, Inc. | Systems and methods for ambulatory generation of nitric oxide |
WO2018183811A1 (en) | 2017-03-31 | 2018-10-04 | The General Hospital Corporation | Systems and methods for a cooled nitric oxide generator |
EP3424550A1 (en) * | 2017-07-06 | 2019-01-09 | Monatomics Technology | Gas mixtures containing low concentrations of xenon and argon provide neuroprotection without inhibiting the catalytic activity of thrombolytic agents |
AU2018358349A1 (en) * | 2017-11-02 | 2020-05-28 | Beyond Air, Inc. | Inhalation of nitric oxide |
US20220111173A1 (en) * | 2018-09-27 | 2022-04-14 | The Regents Of The University Of Michigan | Gas delivery devices |
US11717634B2 (en) | 2018-10-02 | 2023-08-08 | MaxxO2, LLC | Therapeutic oxygen breathing apparatus and exercise system |
US20210386954A1 (en) * | 2018-10-25 | 2021-12-16 | Teijin Pharma Limited | Nitric oxide administration device |
US10682486B1 (en) * | 2019-01-31 | 2020-06-16 | Nu-Med Plus Inc. | Single treatment disposable nitric oxide delivery |
JP6667817B1 (en) * | 2019-03-13 | 2020-03-18 | 住友精化株式会社 | Gas composition, method for producing the same, and gas product |
FR3093926B1 (en) * | 2019-03-22 | 2022-10-28 | Air Liquide | Apparatus and installation for supplying a gas mixture to a patient |
EP3969415A4 (en) | 2019-05-15 | 2023-08-16 | Third Pole, Inc. | Electrodes for nitric oxide generation |
US11479464B2 (en) | 2019-05-15 | 2022-10-25 | Third Pole, Inc. | Systems and methods for generating nitric oxide |
JP7457795B2 (en) * | 2019-08-23 | 2024-03-28 | ノータ ラボラトリーズ,リミティド ライアビリティ カンパニー | Nitric oxide generation system |
AU2020393171A1 (en) | 2019-11-25 | 2022-07-14 | Beyond Air, Inc. | Methods employing gaseous nitric oxide for inhibiting tumor growth |
WO2021142472A1 (en) | 2020-01-11 | 2021-07-15 | Third Pole, Inc. | Systems and methods for nitric oxide generation with humidity control |
WO2021258025A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
EP4405019A1 (en) | 2021-09-23 | 2024-07-31 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4905685A (en) * | 1987-04-14 | 1990-03-06 | Siemens Aktiengesellschaft | Inhalation anaesthesia equipment |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US7955294B2 (en) * | 2004-05-11 | 2011-06-07 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
Family Cites Families (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3036584A (en) | 1961-07-18 | 1962-05-29 | Invengineering Inc | Non-rebreathing valve for gas administration |
BE660318A (en) | 1961-08-15 | |||
US4127121A (en) | 1976-09-17 | 1978-11-28 | University Of Utah | Oxygen and anesthesia delivery and monitoring device |
US4191952A (en) | 1978-08-25 | 1980-03-04 | N.A.D., Inc. | Low oxygen flow alarm for anesthesia systems |
US4224941A (en) * | 1978-11-15 | 1980-09-30 | Stivala Oscar G | Hyperbaric treatment apparatus |
JPS55166163A (en) | 1979-06-13 | 1980-12-25 | Citizen Watch Co Ltd | Controller for anesthetic gas |
US4328823A (en) | 1980-05-14 | 1982-05-11 | N.A.D. Inc. | Oxygen flow ratio controller for anesthesia apparatus |
US4336798A (en) | 1980-10-06 | 1982-06-29 | Anthony V. Beran | Medical corrugated respiratory tube |
SE430213B (en) | 1981-03-10 | 1983-10-31 | Siemens Elema Ab | RESPIRATOR INTENDED TO BE CONNECTED TO THE HUMAN OR ANIMAL PATIENTS |
US4442856A (en) | 1981-08-18 | 1984-04-17 | Puritan-Bennett | Oxygen regulator and alarm system for an anesthesia machine |
SE429197B (en) | 1981-10-14 | 1983-08-22 | Frese Nielsen | SAR TREATMENT DEVICE |
DE3401923A1 (en) | 1984-01-20 | 1985-08-01 | Drägerwerk AG, 2400 Lübeck | DEVICE FOR ADDING LIQUID NARCOSIS TO THE BREATHING GAS TO BE PATIENTED |
US4770168A (en) | 1985-12-16 | 1988-09-13 | Tibor Rusz | Electrically controllable anesthesia vaporizer |
US4954526A (en) | 1989-02-28 | 1990-09-04 | The United States Of America As Represented By The Department Of Health And Human Services | Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents |
FR2656218A1 (en) | 1989-12-21 | 1991-06-28 | France Prod Oxygenes Co | Device for local treatment of the human or animal body using gas |
US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
US5159924A (en) | 1990-10-03 | 1992-11-03 | Cegielski Michael J | Method and apparatus for selectively mixing gases |
US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
US5396882A (en) | 1992-03-11 | 1995-03-14 | The General Hospital Corporation | Generation of nitric oxide from air for medical uses |
US5536241A (en) | 1990-12-05 | 1996-07-16 | The General Hospital Corporation | Methods and devices for relaxing smooth muscle contractions |
DE786264T1 (en) * | 1990-12-05 | 2000-11-02 | The General Hospital Corp., Charlestown | Device for treating a pulmonary vasoconstriction and asthma |
DE4105148A1 (en) | 1991-02-20 | 1992-08-27 | Draegerwerk Ag | NARCOSIS DOSE DEVICE |
US5154697A (en) | 1991-04-02 | 1992-10-13 | Topox, Inc. | Collapsible topical hyperbaric apparatus |
NZ249176A (en) | 1992-02-07 | 1996-11-26 | Vasogen Inc | Method of increasing concentration of nitric oxide in blood using ozone and uv radiation |
US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
US5954680A (en) | 1992-06-19 | 1999-09-21 | Augustine Medical, Inc. | Near hyperthermic heater wound covering |
US6200558B1 (en) | 1993-09-14 | 2001-03-13 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
FR2695831B1 (en) | 1992-09-24 | 1994-11-10 | Air Liquide | Installation and method for supplying a gaseous mixture to the respiratory tract of a user. |
US5427797A (en) | 1993-04-06 | 1995-06-27 | Brigham And Women's Hospital | Systemic effects of nitric oxide inhalation |
DE59409834D1 (en) | 1993-04-17 | 2001-09-27 | Messer Griesheim Austria Ges M | Device for the controlled addition of NO to patient breathing air |
GB2279014B (en) | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
SE501074C2 (en) | 1993-07-22 | 1994-11-07 | Siemens Elema Ab | Gas mixture and apparatus for supplying the gas mixture to the lungs of a living being |
SE9302477L (en) | 1993-07-22 | 1995-01-23 | Siemens Elema Ab | Breathing gas supply apparatus |
AU7972294A (en) * | 1993-10-07 | 1995-05-01 | Entremed, Inc | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
EP0722320B1 (en) | 1993-10-08 | 2000-07-19 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Use of nitric oxide-releasing compounds as medicaments for hypoxic cell radiation sensitization |
US5840759A (en) | 1993-10-08 | 1998-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds to protect noncancerous cells from chemotherapeutic agents |
SE9303369L (en) * | 1993-10-12 | 1995-04-13 | Lars Erik Gustafsson | Respiratory device |
GB9320978D0 (en) * | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
WO1995012394A1 (en) | 1993-11-02 | 1995-05-11 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Use of nitric oxide releasing compounds as protective agents in ischemia reperfusion injury |
US5558083A (en) | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
US5514204A (en) | 1994-07-07 | 1996-05-07 | The Boc Group, Inc. | Process for the purification of nitric oxide |
US5615669A (en) | 1994-07-22 | 1997-04-01 | Siemens Elema Ab | Gas mixture and device for delivering the gas mixture to the lungs of a respiratory subject |
US6190704B1 (en) | 1994-09-23 | 2001-02-20 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US6747062B2 (en) | 1994-09-26 | 2004-06-08 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Regulation of wound healing by nitric oxide |
US5519020A (en) | 1994-10-28 | 1996-05-21 | The University Of Akron | Polymeric wound healing accelerators |
US5648101A (en) | 1994-11-14 | 1997-07-15 | Tawashi; Rashad | Drug delivery of nitric oxide |
US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
IT1272861B (en) * | 1995-01-04 | 1997-07-01 | Ausimont Spa | COPOLYMERS OF ETHYLENE WITH TETRAFLUOROETHYLENE AND / OR CHLOROTRIFLUOROETHYLENE, WITH IMPROVED MECHANICAL PROPERTIES AT HIGH TEMPERATURES |
US6063407A (en) | 1995-02-16 | 2000-05-16 | The General Hospital Corporation | Treatment of vascular thrombosis and restenosis with inhaled nitric oxide |
US5823180A (en) | 1995-04-03 | 1998-10-20 | The General Hospital Corporation | Methods for treating pulmonary vasoconstriction and asthma |
US5722392A (en) | 1995-05-19 | 1998-03-03 | University Of Florida | Breathable gas mixing devices, breathing systems and methods |
SE506208C2 (en) * | 1995-07-05 | 1997-11-24 | Aerocrine Systems Kb | Device for collecting gas from the upper respiratory tract and delivering this gas to the inhalation air in a respirator |
GB9515807D0 (en) | 1995-08-02 | 1995-10-04 | Cantwell Evelyna D | Topical hyperbaric bandage |
JP3139364B2 (en) | 1995-11-29 | 2001-02-26 | 松下電器産業株式会社 | cabinet |
SE9504310D0 (en) | 1995-12-01 | 1995-12-01 | Siemens Elema Ab | dosing device |
WO1997031670A1 (en) | 1996-02-27 | 1997-09-04 | Intensive Care Innovations Ltd. | Ventilatory system with additional gas administrator |
US5725492A (en) * | 1996-03-04 | 1998-03-10 | Cormedics Corp | Extracorporeal circulation apparatus and method |
AP897A (en) | 1996-04-05 | 2000-11-17 | Massachusetts Gen Hospital | Use of gaseous nitric oxide for the manufacturing of a therapeutic gas for the treatment of hemoglobinopathy. |
US5765548A (en) | 1996-05-07 | 1998-06-16 | Perry; Bryan J. | Use of nitric oxide in the treatment of exercised induced pulmonary hemorrhaging in equine |
US5810795A (en) | 1996-05-13 | 1998-09-22 | Westwood; Joseph R. | Hyperbaric device with secondary pressure zone |
US5692497A (en) | 1996-05-16 | 1997-12-02 | Children's Medical Center Corporation | Microprocessor-controlled ventilator system and methods |
US5688236A (en) | 1996-05-17 | 1997-11-18 | Stephen's Medical, Inc. | Topical hyperbaric device for treating skin disorders |
US5848998A (en) | 1996-07-11 | 1998-12-15 | Marasco, Jr.; Patrick V. | Tissue debriding apparatus |
SE9602959L (en) * | 1996-08-12 | 1998-02-09 | Siemens Elema Ab | Process for mixing gases and a device for mixing gases |
US5732693A (en) | 1996-10-02 | 1998-03-31 | Ohmeda Inc. | Pause control of nitric oxide therapy |
JP3207365B2 (en) | 1996-11-28 | 2001-09-10 | 株式会社タイコーデバイス | Manufacturing method of electromagnetic relay |
US6110895A (en) | 1996-12-16 | 2000-08-29 | University Of Southern California | Method of promoting healing in skin grafts |
DE59813457D1 (en) * | 1997-01-17 | 2006-05-11 | Ino Therapeutics Gmbh Brunn Am | CONTROLLED GAS SUPPLY SYSTEM |
DE19701617A1 (en) * | 1997-01-17 | 1998-07-23 | Messer Griesheim Gmbh | Respiration system with sequence-controlled, non-uniform gas metering or sensor-controlled gas-metering |
WO1998033379A1 (en) | 1997-02-04 | 1998-08-06 | The General Hospital Corporation | A novel method for treating epidermal or dermal conditions |
CA2225013C (en) * | 1997-04-04 | 2006-06-06 | Institut Du N.O. Inc. | Injection system for delivery of a gaseous substance |
JP4570696B2 (en) | 1997-04-10 | 2010-10-27 | ジョンズ・ホプキンズ・ユニバーシティ | Gas syringe device |
US5918596A (en) * | 1997-04-22 | 1999-07-06 | Instrumentarium Corp. | Special gas dose delivery apparatus for respiration equipment |
US6571790B1 (en) | 1997-05-12 | 2003-06-03 | Robert E. Weinstein | Method and device for organizing and coordinating the combined use of liquid medications for continuous nebulization for the treatment of respiratory disorders |
US6125846A (en) | 1997-05-16 | 2000-10-03 | Datex-Ohmeda, Inc. | Purge system for nitric oxide administration apparatus |
US6164276A (en) | 1997-05-16 | 2000-12-26 | Datex-Ohmeda, Inc. | Accurate dose nitric oxide pulse delivery device with monitoring and alarms |
WO1999001427A2 (en) | 1997-07-03 | 1999-01-14 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health | Novel nitric oxide-releasing amidine- and enamine-derived diazeniumdiolates, compositions and uses thereof and method of making same |
US6067983A (en) | 1997-09-19 | 2000-05-30 | Sensormedics Corporation | Method and apparatus for controlled flow sampling from the airway |
US6796966B2 (en) | 1997-10-15 | 2004-09-28 | Jeffrey E. Thomas | Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal |
JP2001519386A (en) | 1997-10-15 | 2001-10-23 | トーマス・ジェファーソン・ユニバーシティ | Nitric oxide donor compositions, methods, devices and kits for preventing or reducing vasoconstriction or vasospasm in mammals |
US6109260A (en) | 1998-02-18 | 2000-08-29 | Datex-Ohmeda, Inc. | Nitric oxide administration device with timed pulse |
US6142147A (en) * | 1998-03-31 | 2000-11-07 | The General Hospital Corporation | Nasal delivery system for inhaled nitric oxide |
US6060020A (en) | 1998-04-09 | 2000-05-09 | S.P.M. Recovery Technologies Ltd | Method and apparatus for treating objects with ozone |
US6131572A (en) | 1998-05-20 | 2000-10-17 | Instrumentarium Oy | Medical dosing device having dosing chamber with a pressure sensor |
US6089229A (en) | 1998-05-26 | 2000-07-18 | Datex-Ohmeda, Inc. | High concentration no pulse delivery device |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
US6073627A (en) | 1998-07-30 | 2000-06-13 | Medizone International, Inc. | Apparatus for the application of ozone/oxygen for the treatment of external pathogenic conditions |
CA2350883A1 (en) | 1998-11-23 | 2000-06-02 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
CA2254645A1 (en) * | 1998-11-23 | 2000-05-23 | Pulmonox Medical Corporation | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
US20070086954A1 (en) | 1998-11-23 | 2007-04-19 | Miller Christopher C | Method and apparatus for treatment of respiratory infections by nitric oxide inhalation |
GB2349092B (en) | 1999-03-03 | 2001-07-25 | Per Gisle Djupesland | Nasal delivery device |
US6581599B1 (en) | 1999-11-24 | 2003-06-24 | Sensormedics Corporation | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
DE19961206A1 (en) * | 1999-12-18 | 2001-07-05 | Messer Austria Gmbh Gumpoldski | Tidal volume-dependent gas dosing |
JP2001178817A (en) | 1999-12-24 | 2001-07-03 | Terumo Corp | Device for artificial kidney, quality evaluating device using the same and fluid circuit |
US6758214B2 (en) | 2000-01-28 | 2004-07-06 | Cyterra Corporation | Simple nitric oxide generator for ambulatory and/or bedside inhaled no treatment |
US6811965B2 (en) | 2000-03-08 | 2004-11-02 | Yoram Vodovotz | Kidney perfusion solution containing nitric oxide donor, inhibitor of NOS2, glutathione, gluconate and methods of use |
US20050142217A1 (en) | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US7678391B2 (en) | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
US6270779B1 (en) | 2000-05-10 | 2001-08-07 | United States Of America | Nitric oxide-releasing metallic medical devices |
US6601580B1 (en) | 2000-06-28 | 2003-08-05 | The General Hospital Corporation | Enhancing therapeutic effectiveness of nitric oxide inhalation |
US6668828B1 (en) * | 2000-10-16 | 2003-12-30 | Pulmonox Technologies Corporations | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
US20020069877A1 (en) | 2000-12-13 | 2002-06-13 | Villareal Daniel C. | Ventilation transport device |
US6780849B2 (en) | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
US6432077B1 (en) | 2000-12-26 | 2002-08-13 | Sensormedics Corporation | Device and method for treatment of surface infections with nitric oxide |
US20040009238A1 (en) * | 2002-07-09 | 2004-01-15 | Chris Miller | Exogenenous nitric oxide gas (gNO) therapy in wound healing |
US7335181B2 (en) | 2000-12-26 | 2008-02-26 | Pulmonox Technologies Corporation | Nitric oxide decontamination of the upper respiratory tract |
US7122018B2 (en) | 2000-12-26 | 2006-10-17 | Sensormedics Corporation | Device and method for treatment of wounds with nitric oxide |
US6706274B2 (en) | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
JP4681132B2 (en) | 2001-01-29 | 2011-05-11 | 味の素株式会社 | Nitric oxide synthase production promoter and cosmetic or pharmaceutical composition |
ZA200306564B (en) | 2001-02-26 | 2004-10-15 | Optinose As | Nasal devices. |
US20020138051A1 (en) * | 2001-03-26 | 2002-09-26 | Hole Douglas R. | System and method for the prevention and treatment of animal wound infections using nitric oxide |
US20020155164A1 (en) | 2001-04-18 | 2002-10-24 | Curtis Figley | System and method for the prevention of infections in human patients using nitric oxide |
US20030228564A1 (en) | 2001-05-30 | 2003-12-11 | Edrich Richard Alan | Nitric oxide in a pathogen inactivation process |
KR100382183B1 (en) | 2001-07-26 | 2003-05-09 | 주식회사 자광 | Pharmaceutical composition for increasing the production of nitric oxide and IFN-γ, and process for the preparation thereof |
US6867194B2 (en) | 2001-08-09 | 2005-03-15 | Wayne State University | Enzyme activated nitric oxide donors |
US7040313B2 (en) * | 2001-09-05 | 2006-05-09 | Cyterra Corporation | Method and apparatus for nitric oxide generation |
US6673338B1 (en) | 2001-09-10 | 2004-01-06 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing imidate and thioimidate diazeniumdiolates, compositions, uses thereof and method of making same |
US6703046B2 (en) | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
US6472390B1 (en) | 2001-11-13 | 2002-10-29 | Duke University | Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure |
US6920876B2 (en) | 2001-12-10 | 2005-07-26 | Pulmonox Technologies Corporation | Device for administration of nitric oxide to horses spontaneously breathing |
WO2003066109A1 (en) | 2002-02-08 | 2003-08-14 | Gambro, Inc. | Nitric oxide in a pathogen inactivation process |
AU2003230715A1 (en) | 2002-03-21 | 2003-10-08 | The University Of Utah Research Foundation | In vivo use of glutathionone s-transferase activated nitric oxide donors |
US20030203915A1 (en) | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
EP1507526A2 (en) | 2002-05-07 | 2005-02-23 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Polydiazeniumdiolated cyclic polyamines with polyphasic nitric oxide release and related compounds, compositions comprising same and methods of using same |
EP1509236A4 (en) | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
CA2490392A1 (en) | 2002-06-21 | 2003-12-31 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation |
US20070065473A1 (en) | 2002-07-09 | 2007-03-22 | Miller Christopher C | Nitric oxide gas (gO) as a cosmetic and wound healing agent |
US6949530B2 (en) | 2002-07-18 | 2005-09-27 | The United States Of America As Represented By The Department Of Health And Human Services | Nitric oxide-releasing amidine diazeniumdiolates, compositions and uses thereof and method of making same |
CA2493082A1 (en) | 2002-07-26 | 2004-02-05 | Merck Frosst Canada & Co. | Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
US20040081580A1 (en) | 2002-09-10 | 2004-04-29 | Doug Hole | Use of nitric oxide and a device in the therapeutic management of pathogens in mammals |
US20030039697A1 (en) | 2002-09-12 | 2003-02-27 | Yi-Ju Zhao | Matrices containing nitric oxide donors and reducing agents and their use |
US6854405B2 (en) | 2002-10-15 | 2005-02-15 | Cnh America Llc | Internal tank augers for air seeder hoppers |
US6938357B2 (en) | 2003-09-09 | 2005-09-06 | Carter Day International, Inc. | Forced air circulation for centrifugal pellet dryer |
US7485324B2 (en) | 2003-09-29 | 2009-02-03 | Pulmonox Technologies Corporation | Use of exogenous gaseous nitric oxide in the treatment and disinfection of biofilms |
US20050217668A1 (en) | 2003-10-24 | 2005-10-06 | Pulmonox Technologies Corporation | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
US20080287407A1 (en) | 2003-12-10 | 2008-11-20 | Nitromed, Inc. | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use |
US20050251117A1 (en) | 2004-05-07 | 2005-11-10 | Anderson Robert S | Apparatus and method for treating biological external tissue |
WO2005110052A2 (en) | 2004-05-11 | 2005-11-24 | Pulmonox Technologies Corporation | The use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
US8518457B2 (en) | 2004-05-11 | 2013-08-27 | Pulmonox Technologies Corporation | Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant |
WO2005112954A1 (en) | 2004-05-14 | 2005-12-01 | William Marsh Rice University | Nitric oxide releasing compositions and associated methods |
US20060008529A1 (en) | 2004-07-12 | 2006-01-12 | Meyerhoff Mark E | Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers |
-
2005
- 2005-05-11 US US11/596,027 patent/US20080029093A1/en not_active Abandoned
- 2005-05-11 AU AU2005244078A patent/AU2005244078A1/en not_active Abandoned
- 2005-05-11 CA CA002563493A patent/CA2563493A1/en not_active Abandoned
- 2005-05-11 MX MXPA06013111A patent/MXPA06013111A/en unknown
- 2005-05-11 WO PCT/US2005/016427 patent/WO2005110441A2/en not_active Application Discontinuation
- 2005-05-11 EP EP05747498A patent/EP1755715A4/en not_active Withdrawn
- 2005-05-11 JP JP2007513298A patent/JP2007537267A/en active Pending
- 2005-05-11 CN CN200580014839XA patent/CN1950120B/en not_active Expired - Fee Related
-
2006
- 2006-11-10 US US11/598,221 patent/US7955294B2/en active Active
-
2011
- 2011-01-14 US US13/007,273 patent/US20110226241A1/en not_active Abandoned
-
2012
- 2012-02-08 US US13/369,205 patent/US9095534B2/en active Active
-
2015
- 2015-07-20 US US14/804,114 patent/US20150320963A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4905685A (en) * | 1987-04-14 | 1990-03-06 | Siemens Aktiengesellschaft | Inhalation anaesthesia equipment |
US7516742B2 (en) * | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
US7955294B2 (en) * | 2004-05-11 | 2011-06-07 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
US9095534B2 (en) * | 2004-05-11 | 2015-08-04 | Sensormedics Corporation | Intermittent dosing of nitric oxide gas |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021224894A1 (en) * | 2020-05-08 | 2021-11-11 | Kersten Erich | Ventilator and method of ventilation |
WO2024086364A1 (en) * | 2022-10-21 | 2024-04-25 | Vero Biotech Inc. | Systems, methods, and apparatus for producing nitric oxide |
Also Published As
Publication number | Publication date |
---|---|
US20070144515A1 (en) | 2007-06-28 |
US20110226241A1 (en) | 2011-09-22 |
US7955294B2 (en) | 2011-06-07 |
CN1950120B (en) | 2010-10-20 |
EP1755715A2 (en) | 2007-02-28 |
CA2563493A1 (en) | 2005-11-24 |
MXPA06013111A (en) | 2007-05-23 |
CN1950120A (en) | 2007-04-18 |
WO2005110441A2 (en) | 2005-11-24 |
US20080029093A1 (en) | 2008-02-07 |
US20120199123A1 (en) | 2012-08-09 |
AU2005244078A1 (en) | 2005-11-24 |
WO2005110441A3 (en) | 2006-02-16 |
EP1755715A4 (en) | 2010-03-24 |
US9095534B2 (en) | 2015-08-04 |
JP2007537267A (en) | 2007-12-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9095534B2 (en) | Intermittent dosing of nitric oxide gas | |
US7516742B2 (en) | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing | |
US20210213235A1 (en) | Systems And Methods Of Administering A Pharmaceutical Gas To A Patient | |
ES2579432T3 (en) | System for administering a pharmaceutical gas to a patient | |
EP1519768B1 (en) | Apparatus for the administration of co | |
US20040081580A1 (en) | Use of nitric oxide and a device in the therapeutic management of pathogens in mammals | |
JP2008536871A (en) | Nitric oxide purification of upper airway | |
US10549062B2 (en) | Device for the treatment of, treatment of complications arising from, and/or prevention of respiratory disorders caused by bacterial, viral, protozoal, fungal and/or microbial infections, preferably for the treatment of complications arising from cystic fibrosis | |
AU2014201260B2 (en) | System and method of administering a pharmaceutical gas to a patient | |
US20170304580A1 (en) | Device for ventilating a patient and method for operating a device for ventilating a patient | |
MX2008003829A (en) | System and method of administering a pharmaceutical gas to a patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PULMONOX TECHNOLOGIES CORPORATION, CANADA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MILLER, CHRISTOPHER;MCMULLIN, BEVIN;SIGNING DATES FROM 20060111 TO 20060203;REEL/FRAME:036156/0885 Owner name: SENSORMEDICS CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STENZLER, ALEX;REEL/FRAME:036156/0882 Effective date: 20060106 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |